M. Ibrahim

发表

Selective enhancement of gene transfer by steroid-mediated gene delivery

Merdol Ibrahim, Sandro Rusconi, Maurizio Ceppi, 2001, Nature Biotechnology.

TCH346 prevents motor symptoms and loss of striatal FDOPA uptake in bilaterally MPTP-treated primates

A. Cools, K. Leenders, S. Eshuis, 2003, Neurobiology of Disease.

Standardization of Positive Controls in Diagnostic Immunohistochemistry: Recommendations From the International Ad Hoc Expert Committee

Clive R. Taylor, B. Gilks, P. Swanson, 2015, Applied immunohistochemistry & molecular morphology : AIMM.

Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine: Part 1 Fit-for-Purpose Approach to Classification of Clinical Immunohistochemistry Biomarkers

Clive R. Taylor, Jacqueline A. Hall, A. Marchetti, 2017, Applied immunohistochemistry & molecular morphology : AIMM.

Chromogenic in situ hybridization: a multicenter study comparing silver in situ hybridization with FISH.

I. Ellis, B. Jasani, F. Campbell, 2009, American journal of clinical pathology.

Potential for false-positive staining with a rabbit monoclonal antibody to progesterone receptor (SP2): findings of the UK National External Quality Assessment Scheme for Immunocytochemistry and FISH highlight the need for correct validation of antibodies on introduction to the laboratory.

B. Jasani, M. Ibrahim, A. Dodson, 2008, American journal of clinical pathology.

Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine: Part 4 Tissue Tools for Quality Assurance in Immunohistochemistry

Clive R. Taylor, Jacqueline A. Hall, A. Marchetti, 2017, Applied immunohistochemistry & molecular morphology : AIMM.

A UK NEQAS ISH multicenter ring study using the Ventana HER2 dual-color ISH assay.

N. Collins, B. Jasani, F. Campbell, 2011, American journal of clinical pathology.

‘Breast cancer biomarkers in clinical testing: analysis of a UK NEQAS ICC & ISH database containing results from 199 300 patients’

M. Dowsett, S. Pinder, J. Bartlett, 2020, The journal of pathology. Clinical research.

Breast cancer biomarkers in clinical testing: analysis of a UK national external quality assessment scheme for immunocytochemistry and in situ hybridisation database containing results from 199 300 patients

M. Dowsett, S. Pinder, J. Bartlett, 2018, The journal of pathology. Clinical research.

The identification of a small but significant subset of patients still targetable with anti-HER2 inhibitors when affected by triple negative breast carcinoma

G. Zamboni, G. Tortora, J. Furlanetto, 2013, Journal of Cancer Research and Clinical Oncology.

External quality assurance of HER2 fluorescence in situ hybridisation testing: results of a UK NEQAS pilot scheme

I. Ellis, B. Jasani, E. Kay, 2006, Journal of Clinical Pathology.

HER2 testing in the UK: recommendations for breast and gastric in-situ hybridisation methods

I. Ellis, S. Pinder, B. Jasani, 2011, Journal of Clinical Pathology.

Laser Technologies in Toxicopathology

P. Germann, M. Ibrahim, D. Roman, 2002, Toxicologic pathology.

A UK NEQAS ICC and ISH multicentre study using the Kreatech Poseidon HER2 FISH probe: intersite variation can be rigorously controlled using FISH

I. Ellis, J. Bartlett, F. Campbell, 2010, Histopathology.

Updated UK Recommendations for HER2 assessment in breast cancer

John M S Bartlett, Andrew Hanby, Elena Provenzano, 2014, Journal of Clinical Pathology.

ALK Immunohistochemistry in NSCLC: Discordant Staining Can Impact Patient Treatment Regimen

P. Maxwell, K. Kerr, E. Thunnissen, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine. Part 3: Technical Validation of Immunohistochemistry (IHC) Assays in Clinical IHC Laboratories

Jacqueline A. Hall, A. Marchetti, M. Dietel, 2017, Applied immunohistochemistry & molecular morphology : AIMM.

Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine - Part 2: Immunohistochemistry Test Performance Characteristics.

Keith Miller, Clive R Taylor, Manfred Dietel, 2017, Applied immunohistochemistry & molecular morphology : AIMM.

Standardization of Negative Controls in Diagnostic Immunohistochemistry: Recommendations From the International Ad Hoc Expert Panel

Clive R. Taylor, Mogens Vyberg, Merdol Ibrahim, 2014, Applied immunohistochemistry & molecular morphology : AIMM.

External quality assurance of HER2 FISH and ISH testing: three years of the UK national external quality assurance scheme.

I. Ellis, B. Jasani, A. O'Grady, 2009, American journal of clinical pathology.

Cyclooxygenase-inhibition enhances the effects of rSP-C surfactant therapy in a rat lavage model of acute respiratory distress syndrome (ARDS).

P. Germann, M. Ibrahim, L. Wollin, 2003, Experimental and Toxicological Pathology.

A UK NEQAS ring study evaluating observer variation in the diagnosis of HER2 amplification using the Kreatech™ HER2 FISH probe.

I. Ellis, A. O'Grady, E. Kay, 2009 .

Audit of breast biomarkers markers, HER2.ER & PR in the UK: an update by the UK National External Quality Assessment Scheme for Immunocytochemistry and In Situ Hybridisation (UK NEQAS ICC & ISH)

S. Parry, K. Miller, M. Ibrahim, 2011 .

Nondestructive Quality Control of HER2 Control Cell Line Sections: The use of Interferometry for Measuring Section Thickness and Implications for HER2 Interpretation on Breast Tissue

K. Miller, M. Ibrahim, C. Barker, 2009, Applied immunohistochemistry & molecular morphology : AIMM.

Breast Cancer Biomarkers

J. Bartlett, B. Jasani, K. Miller, 2011 .

Recommendations for HER 2 assessment in breast cancer

I. Ellis, E. Provenzano, S. Pinder, 2015 .

Technical aspects of predictive and prognostic markers in breast cancer: What UK NEQAS data shows

B. Jasani, M. Ibrahim, K. Miller, 2007 .

PD‐L1 testing for lung cancer in the UK: recognizing the challenges for implementation

R. Booton, A. Nicholson, K. Kerr, 2016, Histopathology.

Nondestructive Quality Control of HER 2 Control Cell Line Sections

K. Miller, M. Ibrahim, C. Barker, 2009 .

Interpretation of Immunohistochemical Analysis of MisMatch Repair (MMR) Protein Expression in Tissue Sections for Investigation of Suspected Lynch / Hereditary Non-Polyposis Colorectal Cancer (HNPCC) Syndrome

L. Happerfield, M. Arends, I. Frayling, 2008 .

External Quality Assurance Schemes: The Impact of Participation in the UK Versus Rest of the World: 5 Year Data from the UK National External Quality Assurance Scheme.

B. Jasani, A. O'Grady, E. Kay, 2009 .

Standard Reference Material: Cell Line Development and Use of Reference Cell Lines as Standards for External Quality Assurance of Her2 IHC and ISH Testing

Michael Morgan, John M. S. Bartlett, Jeremy Walker, 2010 .

Abstract P3-10-21: Audit of the Accuracy of Immunohistochemical (IHC) Testing of HER2 Status of Breast Cancer in the United Kingdom: An Interim Analysis

B. Jasani, K. Miller, M. Ibrahim, 2010 .

HNPCC/Lynch Syndrome Module: report of the immunohistochemical analysis of mismatch repair (MMR) protein expression.

L. Happerfield, M. Arends, I. Frayling, 2010 .

Phenotypic Heterogeneity in a Family with a CD40 Ligand Intracellular Domain Mutation

M. Ibrahim, K. Gilmour, P. Yong, 2011, Journal of Clinical Immunology.

Standardization of Positive Controls in Diagnostic Immunohistochemistry: Recommendations From the International Ad Hoc Expert Committee

J. Hornick, E. Torlakovic, M. Ibrahim, 2015, Applied immunohistochemistry & molecular morphology : AIMM.